hapabapa/iStock Editorial via Getty Images
Novo Nordisk's (NVO) anti-obesity therapy Wegovy reduced kidney-related adverse events by 22% in overweight and obese people in a large placebo-controlled study, according to new data published Saturday.
The analysis was based on the company's international SELECT trial, which tested Wegovy, also known as semaglutide, at a dose of 2.4 mg versus placebo as an add-on to standard treatment in more than 17,000 overweight or obese adults.
Professor Helen Colhoun of the University of Edinburgh, lead author of the study, presented the findings on Saturday at the European Renal Congress in Stockholm.
“By addressing key markers of kidney health, semaglutide… may contribute to a significant reduction in the risk of kidney-related complications, including x.com/ERAkidney/status/1794324523749417008″ target=”_blank”>chronic kidney disease and end-stage renal disease,” he said.
The Danish drugmaker has well documented the kidney benefits of semaglutide in the past. In March, the company said that the 1.0 mg dose of the GLP-1 receptor agonist with standard treatment led to a 24% reduction in the risk of kidney disease-related events in patients with type 2 diabetes and disease. chronic kidney.
Novo's (NVO) weight-loss rival Eli Lilly (LLY), which is also testing its obesity drug tirzepatide in kidney-related ailments, traded lower after the announcement.
However, the latest reading “demonstrates for the first time the benefits of semaglutide 2.4 mg in improving kidney function in people with cardiovascular disease and overweight or obesity, without diabetes, a high-risk population with an increased need for kidneys.” protection,” Reuters reported, citing a spokesperson for Novo (NVO).
In August, the company said the SELECT study, designed to evaluate the cardiac benefits of semaglutide, met its primary goal: The weekly injectable led to a 20% reduction in adverse cardiovascular events such as stroke.
